Eli Lilly and Co. (LLY) announced Monday that it's dropping prices for Zepbound single-dose vials sold through LillyDirect, the company's digital healthcare platform. For patients with a valid prescription, this means more affordable access to tirzepatide, the weight-loss medication that's been flying off pharmacy shelves.
The pricing shift is part of Lilly's broader push to lower out-of-pocket costs in the United States, where high drug prices have become a political and practical headache for manufacturers and patients alike.
Here's what the new pricing structure looks like: The starting 2.5 mg dose of Zepbound single-dose vial now costs $299 per month, down from $349. The 5 mg dose drops to $399 monthly from $499. And for patients enrolled in the Zepbound Self Pay Journey Program, all other approved doses are now $449 per month, reduced from $499.
If you're not in the Self Pay Journey Program, regular monthly prices run higher: $599 for the 7.5 mg dose, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for the 15 mg dose.
"We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need," said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
The announcement comes just months after President Donald Trump revealed agreements with Eli Lilly and Novo Nordisk A/S (NVO) to dramatically cut prices on their GLP-1-based obesity and diabetes medications. Those deals will also expand Medicare and Medicaid coverage for these treatments starting in mid-2026.
Under those agreements, starting doses of existing injectables like Wegovy and Zepbound will initially cost $350 a month on TrumpRx, with prices declining to $245 within two years. The upcoming oral versions of these drugs are expected to be even cheaper. Novo Nordisk's oral Wegovy and Lilly's orforglipron are projected to cost $145 a month through Medicare, Medicaid, or TrumpRx once they receive approval.
The price reductions reflect the intense pressure pharmaceutical companies face to make blockbuster weight-loss drugs more accessible. Demand for GLP-1 medications has exploded, but high costs have kept many patients from accessing them, particularly those without insurance coverage.
By offering lower prices directly through LillyDirect, the company is betting that patients will value the convenience and transparency of purchasing medications through a manufacturer-controlled channel rather than navigating traditional pharmacy networks.
Price Action: LLY stock is down 0.72% at $1,067.72 at the last check on Monday.
